KARL SPECTOR: Open Payments
NPI 1164472551 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,063 in 54 payments from 17 companies in 2025. Trend: 2023 $718 · 2024 $1,002 · 2025 $1,063
Food & beverage: $1,063
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $227 |
| AstraZeneca Pharmaceuticals LP | 6 | $121 |
| Lilly USA, LLC | 6 | $114 |
| PFIZER INC. | 5 | $102 |
| Abbott Laboratories | 3 | $64 |
| ABBVIE INC. | 4 | $63 |
| Indivior Inc. | 2 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Almatica Pharma LLC | 2 | $48 |
| Agios Pharmaceuticals, Inc. | 1 | $36 |
Products named: Ozempic, MOUNJARO, FREESTYLE LIBRE 3, SUBLOCADE, AIRSUPRA, VOQUEZNA, LOREEV XR, BREZTRI.
Industry payments across MD — which companies pay providers there.
